MNU-Induced Gastric Cancer Model Service

The MNU-induced gastric cancer model recreates the stepwise emergence of glandular stomach tumors through exposure to a direct-acting alkylating carcinogen, offering a tractable and histologically faithful platform for dissecting stomach tumorigenesis. With deep expertise in chemically induced gastrointestinal oncology models, Alfa Cytology stands ready to construct, monitor, and analyze MNU-driven gastric cancer studies on behalf of its partners, supplying reliable tumor-bearing cohorts together with rigorously documented endpoint data.

Overview of MNU-Induced Gastric Cancer Model

Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, and its development is widely understood to follow a multistage course in which chronic mucosal damage, oxidative stress, and repeated genotoxic insults gradually transform the glandular epithelium. To study this process experimentally, researchers have long relied on N-nitroso compounds, agents that arise endogenously in the stomach from dietary nitrites and that reproduce key features of human stomach cancer in rodents. Among them, N-methyl-N-nitrosourea (MNU) occupies a central position because it is a direct-acting carcinogen that alkylates DNA without requiring enzymatic activation, thereby concentrating its mutagenic effect at the site of exposure.

Fig 1. End-to-end MNU induction SOP: Step 1 MNU solution preparation (0.012 g/50 mL = 240 ppm, light-shielded flask, 10 min), Step 2 five 2-week cycles of alternating 240 ppm MNU water (1 week) and normal water (1 week), Step 3 free feeding and drinking for approximately 22 weeks, Step 4 tissue harvest, photography, and histologic analysis (3 days) — the standard operating procedure for MNU gastric cancer model services. (Li, Ke, et al., 2021)

When MNU is supplied in the drinking water on an alternating-week schedule, rodents develop tumors predominantly in the gastric antrum that are histologically classified as well- or moderately-differentiated adenocarcinomas, resembling the most common form of human gastric malignancy. Because the model requires no surgery, no genetic manipulation, and only a short period of carcinogen exposure followed by a latency phase of tumor outgrowth, it is inexpensive, highly reproducible across strains, and readily combined with co-factors such as Helicobacter pylori infection or high-salt diet to mimic real-world risk environments. These characteristics have made the MNU model a staple of gastric carcinogenesis research, chemoprevention screening, and mechanism validation carried out in vivo.

Principles of MNU-Induced Gastric Cancer Model Construction

The construction of the MNU model hinges on three pillars: a direct-acting alkylating initiator, an intermittent exposure schedule that preserves mucosal viability, and a sufficient post-exposure latency for initiated cells to expand into visible tumors. The individual elements are itemized below.

Our Services

From dose scheduling and light-protected solution handling to serial endoscopy and full-spectrum histopathology, Alfa Cytology manages every operational detail of MNU-induced gastric cancer studies, allowing sponsors to focus squarely on the scientific questions that matter most to their programs.

Workflow of MNU-Induced Gastric Cancer Model Construction

An MNU study unfolds in two distinct phases: a ten-week induction phase built around five alternating exposure cycles, and a latency phase of several months during which tumors emerge and can be monitored or treated. The principal steps are summarized below.

1. Animal receipt and acclimatization: Mice of the selected strain (commonly C57BL/6 or BALB/c, aged 6–8 weeks) are allowed a minimum one-week acclimatization with free access to standard chow and bottled water before any manipulation.
2. Cohort randomization and baseline recording: Animals are randomized to control and treatment groups, and baseline body weights, general condition, and water consumption habits are documented for later comparison.
3. MNU solution preparation: MNU powder is weighed under light-shielded conditions and dissolved fresh in sterile drinking water at the target concentration; solutions are dispensed into foil-wrapped bottles in small batches.
4. Induction phase (5 alternating cycles): MNU water is provided ad libitum for one week, replaced by plain water for the following week, and this two-week cycle is repeated five times, with solutions renewed every other day to offset compound instability.
5. Health and welfare monitoring: Body weight, activity, coat condition, and water intake are tracked throughout induction; predefined humane endpoints govern intervention, and surviving animals transition to the latency phase on regular water.
6. Latency-phase surveillance and intervention: Over the subsequent 18–26 weeks, animals are observed weekly, with optional gastric imaging or sampling time points; test compounds, inhibitors, or dietary modifiers can be administered during this window without carcinogen interference.
7. Endpoint euthanasia and gross examination: At the study endpoint, animals are euthanized humanely; the stomach is excised along the greater curvature, opened, pinned flat, and inspected macroscopically for tumor number, location, and size.
8. Histopathology and molecular analysis: Tissues are fixed, sectioned, and graded through the dysplasia–adenocarcinoma spectrum, complemented by immunohistochemistry, cytokine profiling, and DNA damage marker analysis as required.

Fig 2. MNU-Induced Gastric Cancer Model Construction Workflow.

Case Study-MNU-Induced Gastric Cancer Model Development

Alfa Cytology has executed MNU-based gastric carcinogenesis programs for partners investigating chemopreventive agents, anti-inflammatory strategies, and molecularly targeted interventions. Across these preclinical engagements, the platform has consistently delivered antral tumor formation with well-controlled inter-animal variability, supported by graded histopathology, proliferative and DNA damage marker quantification, and exploratory molecular readouts. Study-specific datasets and representative findings can be made available to interested partners upon inquiry, subject to confidentiality agreements.

Why Choose Alfa Cytology?

Partners engaging Alfa Cytology for MNU model work benefit from disciplined carcinogen handling practices and an endpoint package built specifically for gastric oncology research.

• Tailored model configurations spanning mouse strains, exposure intensities, and optional H. pylori or dietary co-exposures.
• Strict light-protected, small-batch MNU preparation routines that safeguard compound potency and dosing consistency.
• Well-defined humane endpoint criteria and daily welfare oversight throughout the induction and latency phases.
• Comprehensive endpoint suite combining gross tumor mapping, dysplasia-to-carcinoma grading, and gastric biomarker immunohistochemistry.
• Flexible intervention scheduling that isolates the latency phase as a clean therapeutic testing window.
• Ph.D.-led project management delivering concise, decision-ready reports at every study milestone.

Contact Us

If your program calls for a dependable, histologically authentic gastric cancer platform, Alfa Cytology is prepared to help you move forward. Contact us or reach out to our scientific team today for a customized study plan, timeline, and quotation built around your preclinical objectives.

For research use only. Not intended for any clinical use.